Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Nelson

Showing results (471-480 of 521) with videos related to

Pageof 53
Sort By:
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Scientific Reports|June 6, 2015
Chromosome-level genome map provides insights into diverse defense mechanisms in the medicinal fungus Ganoderma sinenseYingjie Zhu, Jiang Xu, Chao Sun, et al.
Pharmacogenomics|March 28, 2017
Institutional profile: University of Florida Health Personalized Medicine ProgramLarisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Cell Host & Microbe|January 12, 2021
Large-scale genome sequencing reveals the driving forces of viruses in microalgal evolutionDavid R Nelson, Khaled M Hazzouri, Kyle J Lauersen, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisJoseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Pageof 53

Showing results (471-480 of 521) with videos related to

Sort By:
Pageof 53
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Scientific Reports|June 6, 2015
Chromosome-level genome map provides insights into diverse defense mechanisms in the medicinal fungus Ganoderma sinenseYingjie Zhu, Jiang Xu, Chao Sun, et al.
Pharmacogenomics|March 28, 2017
Institutional profile: University of Florida Health Personalized Medicine ProgramLarisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Cell Host & Microbe|January 12, 2021
Large-scale genome sequencing reveals the driving forces of viruses in microalgal evolutionDavid R Nelson, Khaled M Hazzouri, Kyle J Lauersen, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisJoseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
Pageof 53